272 related articles for article (PubMed ID: 23724141)
41. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
[TBL] [Abstract][Full Text] [Related]
42. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
43. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures.
Shakibaei M; Buhrmann C; Kraehe P; Shayan P; Lueders C; Goel A
PLoS One; 2014; 9(1):e85397. PubMed ID: 24404205
[TBL] [Abstract][Full Text] [Related]
44. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
[TBL] [Abstract][Full Text] [Related]
45. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
46. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
47. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
48. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
49. Proliferation rate but not mismatch repair affects the long-term response of colon carcinoma cells to 5FU treatment.
Choudhary B; Hanski ML; Zeitz M; Hanski C
Cancer Lett; 2012 Jul; 320(1):56-64. PubMed ID: 22266192
[TBL] [Abstract][Full Text] [Related]
50. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
[TBL] [Abstract][Full Text] [Related]
51. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
52. Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.
Chung H; Chaudhry J; Lopez CG; Carethers JM
Cancer Biol Ther; 2010 Dec; 10(11):1147-56. PubMed ID: 20930505
[TBL] [Abstract][Full Text] [Related]
53. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
[TBL] [Abstract][Full Text] [Related]
54. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
55. MLH1 deficiency enhances tumor cell sensitivity to ganciclovir.
O'Konek JJ; Boucher PD; Iacco AA; Wilson TE; Shewach DS
Cancer Gene Ther; 2009 Sep; 16(9):683-92. PubMed ID: 19300472
[TBL] [Abstract][Full Text] [Related]
56. Hyperthermia effects on Hsp27 and Hsp72 associations with mismatch repair (MMR) proteins and cisplatin toxicity in MMR-deficient/proficient colon cancer cell lines.
Sottile ML; Losinno AD; Fanelli MA; Cuello-Carrión FD; Montt-Guevara MM; Vargas-Roig LM; Nadin SB
Int J Hyperthermia; 2015; 31(5):464-75. PubMed ID: 26043026
[TBL] [Abstract][Full Text] [Related]
57. Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression.
Plaschke J; Krüger S; Jeske B; Theissig F; Kreuz FR; Pistorius S; Saeger HD; Iaccarino I; Marra G; Schackert HK
Cancer Res; 2004 Feb; 64(3):864-70. PubMed ID: 14871813
[TBL] [Abstract][Full Text] [Related]
58. WRN helicase promotes repair of DNA double-strand breaks caused by aberrant mismatch repair of chromium-DNA adducts.
Zecevic A; Menard H; Gurel V; Hagan E; DeCaro R; Zhitkovich A
Cell Cycle; 2009 Sep; 8(17):2769-78. PubMed ID: 19652551
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Zhang X; Yashiro M; Ren J; Hirakawa K
Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
[TBL] [Abstract][Full Text] [Related]
60. An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.
Bailis JM; Gordon ML; Gurgel JL; Komor AC; Barton JK; Kirsch IR
PLoS One; 2013; 8(10):e78726. PubMed ID: 24205301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
